Table 3.
Natural products loaded niosomes for pharmaceutical applications.
| Niosome Type | Natural Product | Production Method | Size (nm) | EE (%) | Disease Type | Products | In-vivo/In-vitro | Results | Ref |
|---|---|---|---|---|---|---|---|---|---|
| LUV | Rice Bran | scCO2 | 480.9 ± 270.8 | 47.54–64.47 | Skin Aging | Anti-aging effects in gel and cream | Rabit Skin/Fibroblast cells | Skin lightning, thickness, roughness and elasticity improvement | [126] |
| LUV | Lycopene | Adsorption-Hydration | 175–235 | 62.8 ± 2 | Diabetes | Anti-Diabetic vesicles | Wistar rat | Efficient delivery. | [130] |
| Blood glucose level reduction | |||||||||
| LUV | Lycopene | Adsorption-Hydration | 170–230 | 62.76 ± 2 | Cervical and breast Cancer | Lycopene encapsulation | MCF-7 and HeLa cells, Wistar rat | Anti-cancer activity | [137] |
| SUV | Zingiber | Film hydration | 100 | – | Inflammation | Wistar rat | Antioxidant and anti-inflammatory | [131] | |
| LUV | Turmeric | Transmembrane pH gradient | 400–500 | 81.69 | Mosquito vectors | Against larvae | Mortality of larvae | [138] | |
| LUV | Embelin | Thin film hydration | 500–700 | 63.32–80.00 | Diabetes | Wistar rat | Hypoglycemic activity | [118] | |
| LUV | Gymnema sylvestre | Thin film hydration | 229.5 ± 30 | 57.8–85.3 | Diabetes | Anti-Diabetic vesicles | Wistar rat | [139] | |
| LUV | Silymarin | Hand Shaking | 256.2–541.1 | 43.8–70.61 | Hepatoprtective | Wistar rat | Increasing drug bioavailability | [140] | |
| LUV | Ellagic acid | Reverse phase evaporation | 124–1776 | 1.35–26.75 | Human skin & Franz diffusion cell | Efficient delivery of EA through epidermis | [141] | ||
| LUV | Ammonium Glycyrrhizinate | Thin film hydration and high-speed stirring | 363–622 | 13.2–40 | Eczema and psoriasis | Dermal administration | – | [142] | |
| LUV | Resveratrol | Thin film hydration | 139–227 | 16.8–72.5 | – | Yoghurt additive | – | – | [143] |
| SUV and LUV | Nerium oleander | Thin film hydration | 59.1–334.0 | 13.24–16.20 | Alveolar type-II and cervical cancer cell | Antioxidant activity | [144] | ||
| LUV | Curcumin | Thin film hydration | 250 ± 20 | 90 | Cancer | Anticancer, anti-tubercular and anti-inflammatory | HeLa | Multi-drug delivery enhancement | [29] |
| LUV | Morusin | Thin film hydration | 479 | 97 | Cancer | Anticancer therapy | MDA-MB-453, HT-29, PANC-1, SKOV-3, and L929 | [145] | |
| SUV | Curcumin | Thin film and pH-gradient | 48–185.9 | 50.21–95.11 | Cancer | Anticancer therapy | Saos-2, MG-63, and KG-1 | Multi hydrophilic and hydrophobic drug delivery | [119] |
| LUV | Papain | Thin film hydration and sonication | 220.7–520.2 | – | Scar of skin | Skin treatment | Sprague-Dawley rats' skin | Skin permeation enhancement | [146] |
| LUV | Gambogenic acid | Ethanol injection | 98.3–299.7 | 36.09–68.20 | Cancer | Anticancer drug candidate | – | Effective release and increasing duration | [22] |
| SUV | Curcumin | Thin film hydration | 101.5–125.1 | 52.24–85.42 | Cancer | Anticancer therapy | MCF-7, MCF-10A | Improving therapeutic effectiveness of cancer treatments | [121] |
| LUV | Green tea | Thin film hydration | 338.3 | 56.39–77.80 | Skin Protection | Antioxidants niosomal gel | – | Efficient encapsulation | [147] |
| LUV | Resveratrol | Thin film hydration and ethanol injection | 284 ± 28–496 ± 39 | 15±1–48 ± 3 | Skin inflammation and irritation | Topical use and delivery | Newborn Pig skin | [125] | |
| SUV | Morin | Thin film hydration | 109–233 | 55.47–78.94 | Cancer and Parkinson | Antioxidant and anticancer activity in brain | Wistar rat | Improvement in AUC of MH | [148] |
| MLV | Ellagic acid | Reverse phase evaporation | 312–560 | 25.63–38.73 | – | Dermal delivery system | Human skin | Permeation enhancement to the skin | [132] |
| LUV | Aloe vera | Reverse phase evaporation | 270.08 | 42.04 | Skin defects and wounds | Skin wound dressing | Fibroblast cell | Accelerating healing process | [149] |
| – | Silibinin | Reverse phase evaporation | – | 49.50–86.38 | Cancer | Anti-tumoural activity | T47D cell | Altering level of miRNA expression | [150] |
| – | Resveratrol | Thin film hydration | – | 97.00 ± 0.02 | – | Hydrogel systems encapsulating niosomes | – | Preventing trans-to-cis photoisomerization of resveratrol | [123] |
| MLV and SUV | Resveratrol | Mechanical agitation and sonication | 200–900 | <40.96 | Antioxidant | Functional food | – | [151] | |
| SUV | Rice Bran | chloroform film method with sonication | 44.86–75.67 | – | – | Anti-hair loss products | Fibroblast cell | [127] | |
| LUV | Ginkgo biloba | Film dispersion–homogenization | 140.9–505.1 | 38.7–57.7 | Auto-oxidation, antitumor, protective in nervous system | Delivery of GbE to the brain | Wistar rat | [152] | |
| – | Curcumin | Ether injection | – | – | – | Transdermal formulation gel | Wistar rat skin | – | [122] |
| LUV | Artemisia absinthium | Thin film hydration | 174 ± 2.56 | 66.73 | Amyloid aggregation | – | [153] | ||
| SUV | Marigold | Thin film hydration | 57.61 ± 25.27 and 82.72 ± 21.92 | 59 | Cytotoxicity, wound healing, antioxidant | Vero cell | [154] | ||
| LUV | Zingiber | 690 and 1930 | – | Anti-inflammatory | Newborn pigs skin and Male ICR mice | Chemical stability and skin permeation enhancement | [155] | ||
| LUV | Propolis | Reverse phase evaporation | 237–333 | 91 ± 0.48 | Oral recurrent aphthous ulcer | Antimicrobial compound | Franz diffusion cell | [156] | |
| SUV | Carum | Thin film hydration | 100–200 | 86.25–92.32 | Cancer | Breast cancer treatment | MCF7 | Novel high efficiency carrier | [157] |